Cargando…

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention

BACKGROUND: Percutaneous treatment of coronary bifurcation lesions can potentially lead to higher risk of ischemic events than the nonbifurcation ones, thus calling for further optimization of dual antiplatelet therapy (DAPT). This study aimed to compare the clinical outcomes from ticagrelor and clo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Wei, Li, Youmei, Tian, Jingdu, Li, Lufeng, Xie, Li, Mao, Qi, Tong, Wuyang, Zhou, Denglu, Azzalini, Lorenzo, Zhao, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448338/
https://www.ncbi.nlm.nih.gov/pubmed/31016189
http://dx.doi.org/10.1155/2019/3170957
_version_ 1783408683197136896
author Zheng, Wei
Li, Youmei
Tian, Jingdu
Li, Lufeng
Xie, Li
Mao, Qi
Tong, Wuyang
Zhou, Denglu
Azzalini, Lorenzo
Zhao, Xiaohui
author_facet Zheng, Wei
Li, Youmei
Tian, Jingdu
Li, Lufeng
Xie, Li
Mao, Qi
Tong, Wuyang
Zhou, Denglu
Azzalini, Lorenzo
Zhao, Xiaohui
author_sort Zheng, Wei
collection PubMed
description BACKGROUND: Percutaneous treatment of coronary bifurcation lesions can potentially lead to higher risk of ischemic events than the nonbifurcation ones, thus calling for further optimization of dual antiplatelet therapy (DAPT). This study aimed to compare the clinical outcomes from ticagrelor and clopidogrel in bifurcation lesions patients undergoing percutaneous coronary intervention (PCI). METHODS: We performed a retrospective cohort study in patients with coronary bifurcation lesions. A total of 553 patients discharged on ticagrelor or clopidogrel combined with aspirin were recruited for 1-year follow-up. The incidences of primary endpoint (major adverse cardiovascular event [MACE]: a composite of cardiac death, myocardial infarction [MI] or stroke), secondary endpoints (the individual component of the primary endpoint or definite/probable stent thrombosis), and major bleeding (Bleeding Academic Research Consortium [BARC]≥3 bleeding events) were evaluated. To minimize the selection bias, a propensity score-matched population analysis was also conducted. RESULTS: The risks of both primary endpoint (8.15% and 12.01% for the ticagrelor and clopidogrel groups, respectively; adjusted hazards ratio [HR]: 0.488, 95% confidence interval [CI]: 0.277-0.861, P=0.013) and MI (4.44% and 8.48% for the ticagrelor and clopidogrel groups, respectively; adjusted HR: 0.341, 95% CI: 0.162-0.719, P=0.005) were significantly reduced in the ticagrelor group as compared with those of the clopidogrel counterpart, whereas the risk of major bleeding was comparable (2.96% and 2.47% for the ticagrelor and clopidogrel groups, respectively; adjusted HR: 0.972, 95% CI: 0.321-2.941, P=0.960). Propensity score-matched analysis confirmed such findings. CONCLUSIONS: For patients with bifurcation lesions after PCI, ticagrelor treatment shows lower MACE and MI rates than the clopidogrel one, along with comparable major bleeding.
format Online
Article
Text
id pubmed-6448338
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-64483382019-04-23 Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention Zheng, Wei Li, Youmei Tian, Jingdu Li, Lufeng Xie, Li Mao, Qi Tong, Wuyang Zhou, Denglu Azzalini, Lorenzo Zhao, Xiaohui Biomed Res Int Research Article BACKGROUND: Percutaneous treatment of coronary bifurcation lesions can potentially lead to higher risk of ischemic events than the nonbifurcation ones, thus calling for further optimization of dual antiplatelet therapy (DAPT). This study aimed to compare the clinical outcomes from ticagrelor and clopidogrel in bifurcation lesions patients undergoing percutaneous coronary intervention (PCI). METHODS: We performed a retrospective cohort study in patients with coronary bifurcation lesions. A total of 553 patients discharged on ticagrelor or clopidogrel combined with aspirin were recruited for 1-year follow-up. The incidences of primary endpoint (major adverse cardiovascular event [MACE]: a composite of cardiac death, myocardial infarction [MI] or stroke), secondary endpoints (the individual component of the primary endpoint or definite/probable stent thrombosis), and major bleeding (Bleeding Academic Research Consortium [BARC]≥3 bleeding events) were evaluated. To minimize the selection bias, a propensity score-matched population analysis was also conducted. RESULTS: The risks of both primary endpoint (8.15% and 12.01% for the ticagrelor and clopidogrel groups, respectively; adjusted hazards ratio [HR]: 0.488, 95% confidence interval [CI]: 0.277-0.861, P=0.013) and MI (4.44% and 8.48% for the ticagrelor and clopidogrel groups, respectively; adjusted HR: 0.341, 95% CI: 0.162-0.719, P=0.005) were significantly reduced in the ticagrelor group as compared with those of the clopidogrel counterpart, whereas the risk of major bleeding was comparable (2.96% and 2.47% for the ticagrelor and clopidogrel groups, respectively; adjusted HR: 0.972, 95% CI: 0.321-2.941, P=0.960). Propensity score-matched analysis confirmed such findings. CONCLUSIONS: For patients with bifurcation lesions after PCI, ticagrelor treatment shows lower MACE and MI rates than the clopidogrel one, along with comparable major bleeding. Hindawi 2019-03-20 /pmc/articles/PMC6448338/ /pubmed/31016189 http://dx.doi.org/10.1155/2019/3170957 Text en Copyright © 2019 Wei Zheng et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zheng, Wei
Li, Youmei
Tian, Jingdu
Li, Lufeng
Xie, Li
Mao, Qi
Tong, Wuyang
Zhou, Denglu
Azzalini, Lorenzo
Zhao, Xiaohui
Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
title Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
title_full Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
title_fullStr Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
title_full_unstemmed Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
title_short Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
title_sort effects of ticagrelor versus clopidogrel in patients with coronary bifurcation lesions undergoing percutaneous coronary intervention
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448338/
https://www.ncbi.nlm.nih.gov/pubmed/31016189
http://dx.doi.org/10.1155/2019/3170957
work_keys_str_mv AT zhengwei effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT liyoumei effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT tianjingdu effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT lilufeng effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT xieli effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT maoqi effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT tongwuyang effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT zhoudenglu effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT azzalinilorenzo effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention
AT zhaoxiaohui effectsofticagrelorversusclopidogrelinpatientswithcoronarybifurcationlesionsundergoingpercutaneouscoronaryintervention